Top Markets
#1 Black Phoenix Black Phoenix +357.53%
#2 Islamic Coin Islamic Coin +158.14%
#3 Glidr Glidr +58.56%
#4 Cryptopia Cryptopia +19.93%
#5 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +18.49%
#6 Victoria VR Victoria VR +7.35%
#7 Pons Pons +6.63%
#8 COTI COTI +6.01%
#9 Movement Movement +5.28%
#10 Palladium Network Palladium Network +5.16%
Coin of the day
Black Phoenix Black Phoenix
Ustawienia
Język
POLSKI
Waluta
USD
Motyw
VIA Pharmaceuticals, Inc. VIA Pharmaceuticals, Inc.

VIA Pharmaceuticals, Inc.

VIAP
Pozycja w akcjach #41780
VIA Pharmaceuticals, Inc. is an emerging biotechnology company primarily... VIA Pharmaceuticals, Inc. is an emerging biotechnology company primarily focused on discovering and advancing therapeutic compounds for cardiovascular and metabolic disorders. The firm is building a portfolio of small-molecule drug candidates designed to tackle the root causes of these health issues, such as vascular inflammation, elevated cholesterol and triglyceride levels, and insulin resistance or diabetes. Notable candidates in their development pipeline include: VIA-3196: A liver-specific thyroid hormone receptor (THR) beta agonist, poised for Phase 1 clinical studies. This drug aims to mitigate dyslipidemia, addressing high LDL cholesterol, elevated triglycerides, and Lp(a) levels. A Diacylglycerol Acyl Transferase 1 (DGAT1) inhibitor: Currently in preclinical development for treating type 2 diabetes, with promising potential for weight management and other lipid disorders. VIA-2291: A 5-Lipoxygenase inhibitor that has successfully completed its third Phase 2 clinical trial. Its purpose is to target atherosclerotic plaque, a significant contributor to heart attacks, strokes, and various other vascular diseases. VIA Pharmaceuticals has also forged two research, development, and commercialization agreements with Hoffman-LaRoche Inc. and Hoffman-LaRoche Ltd. These collaborations pertain to their THR beta agonist program and several compounds from their preclinical DGAT1 metabolic disorders initiative. Established in 2004, the company's headquarters are located in San Francisco, California.
Cena akcji
$0.0005
Ostatnia synchronizacja: 2026-08-11
Kapitalizacja rynkowa
$10.28K
Zmiana (1 dzień)
0.00%
Zmiana (1 rok)
0.00%
Kraj
US
Handel VIA Pharmaceuticals, Inc. (VIAP)

Kategoria

Healthcare
Cena VIAP z kapitalizacją rynkową B
VIA Pharmaceuticals, Inc. VIA Pharmaceuticals, Inc.
VIAP
$0.0005
Kapitalizacja rynkowa VIA Pharmaceuticals, Inc.(VIAP)
Kapitalizacja rynkowa: $10.28K
Na dzień August 2026 spółka VIA Pharmaceuticals, Inc. ma kapitalizację rynkową wynoszącą $10.28K. Według naszych danych, czyni to VIA Pharmaceuticals, Inc. 41780th najcenniejszą firmą na świecie pod względem kapitalizacji rynkowej. Kapitalizacja rynkowa to całkowita wartość rynkowa wszystkich wyemitowanych akcji spółki giełdowej i jest powszechnie stosowana do oceny jej wartości.
Historia kapitalizacji rynkowej VIA Pharmaceuticals, Inc. od 2007 do 2026
VIAP w porównaniu do 5 najpopularniejszych stocks
Cena za VIAP Aktywa B Kapitalizacja rynkowa B Wyniki
VIA Pharmaceuticals, Inc. VIA Pharmaceuticals, Inc.
$261,862 $10.28K
NVIDIA Corporation NVIDIA Corporation
NVDA
$5.383T +52,372,404,414.06%
VIA Pharmaceuticals, Inc. VIA Pharmaceuticals, Inc.
$215,166 $10.28K
Apple Inc. Apple Inc.
AAPL
$4.423T +43,033,283,329.69%
VIA Pharmaceuticals, Inc. VIA Pharmaceuticals, Inc.
$202,372 $10.28K
Alphabet Inc. Alphabet Inc.
GOOG
$4.160T +40,474,456,550.28%
VIA Pharmaceuticals, Inc. VIA Pharmaceuticals, Inc.
$178,194 $10.28K
Microsoft Corporation Microsoft Corporation
MSFT
$3.663T +35,638,883,419.80%
VIA Pharmaceuticals, Inc. VIA Pharmaceuticals, Inc.
$140,638 $10.28K
Amazon.com, Inc. Amazon.com, Inc.
AMZN
$2.891T +28,127,529,770.61%